Background {#Sec1}
==========

Cancer is the second leading cause of death worldwide \[[@CR1]\], with 8.8 million cancer deaths in 2015 \[[@CR1]\], and over 14 million new cancer cases diagnosed in 2012 \[[@CR2]\]. About 30% of cancer deaths occurred in high-income countries \[[@CR1]\]. Cancer screening programs have the potential to reduce cancer-specific and possibly all-cause mortality \[[@CR3], [@CR4]\]. The United States Preventive Services Task Force (USPSTF) has concluded that there is at least adequate evidence of a net benefit for screening for lung, breast, cervical, and colorectal cancers \[[@CR5]--[@CR8]\], and screening programs for cancer are widespread in other high resource countries \[[@CR3], [@CR4], [@CR9]--[@CR11]\]. For example, of over 31 million women eligible for breast cancer screening in European countries, 79% were invited to screen and 49% were screened \[[@CR3]\]. Breast cancer mortality has decreased in the USA from 31.4 to 20.5 deaths per 100,000 women between 1975 and 2014, with similar trends in Europe, an effect attributable to both screening and improved treatment \[[@CR12]\].

Cancer screening programs have largely been implemented in high-income countries with greater available resources \[[@CR9], [@CR13], [@CR14]\]. However, there is considerable variation in terms of screening methods, starting age, stopping age, and screening interval between countries \[[@CR3], [@CR4], [@CR9]\]. For example, the USPSTF recommends that adults aged 50 to 75 years should be screened for colorectal cancer with one of seven tests or combinations of tests (including colonoscopy), \[[@CR8]\] while the Canadian Task Force on Preventive Health Care does not recommend colonoscopy as a screening test \[[@CR15]\]. In Europe, even after the European Union recommendations in 2003, the implementation of the Council recommendations differs between countries \[[@CR3]\]. We hypothesize that countries spending more on healthcare per capita will have more intensive cancer screening recommendations, screening for more cancers over a longer age range, and at a shorter screening interval ([Appendix](#Sec16){ref-type="sec"}).

In the current report, we will review and compare cancer screening recommendations implemented in 21 high resource countries that in 2015 spent at least \$3000 per capita on healthcare. We will review national recommendations where available, or the most relevant other guidelines for that country where national or federal recommendations such as those of the USPSTF do not exist. The cancers addressed will include breast, cervical, colorectal, prostate, skin, and lung cancer. As a point of comparison with US national guidelines from the USPSTF, we include relevant specialty society guidelines from the American College of Radiology, American College of Obstetrics and Gynecology, and others.

Methods {#Sec2}
=======

The goal of the study was to compare cancer screening recommendations in countries with comparable levels of healthcare spending, and to try to understand the relationship between healthcare spending and the intensity of screening recommendations. Membership in the Organization for Economic Cooperation and Development (OECD) was chosen as the initial qualification for inclusion in the study to ensure that the countries compared were similar economically. It was then decided that total health expenditure per capita was the most relevant statistic to national cancer screening recommendations. Therefore, the 35 OECD member countries were rank ordered according to total healthcare expenditure per capita using data from 2015. From this ranked list, all countries that spent over USD3000 per capita on health that year were included (*n* = 21) \[[@CR16]\].

The next step was to determine which national organization's cancer screening guidelines would be chosen as that country's national recommendations. First, colleagues of the authors in each country of the study were consulted as local content experts. This was supplemented by searches of the internet where necessary. Once the national recommendations were determined for each country, the data were abstracted in tandem by two members of the research team, consulting with the project leader (Dr. Ebell) to resolve any discrepancies.

To create a uniform grading scheme, each screening test for each type of cancer was graded as *recommended* (which includes both strongly recommended and recommended*)*, *recommended selectively*, *recommended against*, or *insufficient evidence*, corresponding to the categories used by the US Preventive Services Task Force. After analysis of each country's national screening recommendations, the data were organized into tables. Finally, screening intensity was defined for breast, cervical, and colorectal cancer as the total number of lifetime screening tests recommended for an average risk person.

Results {#Sec3}
=======

Information for the organizations making screening recommendations is shown in Table [1](#Tab1){ref-type="table"}. We abstracted the screening's recommendations from national guideline committee's websites for 15 out of the 21 selected countries. The other countries' recommendations are from cancer society's websites. Notably, for the USA, beside the United Stated Preventive Services Task Force (USPSTF), we additionally abstracted the recommendations from the American Cancer Society (since it is widely used by US physicians) and three specialty society's websites.Table 1Organizations making screening recommendations, by countryCountryOrganization NameType of organizationUnited StatesUnited States Preventive Services Task ForceNational guideline committeeUnited StatesAmerican Cancer SocietyCancer societyUnited StatesAmerican College of Obstetrics & GynecologySpecialty societyUnited StatesAmerican College of RadiologySpecialty societyUnited StatesAmerican Urological AssociationSpecialty societyLuxembourgMinistry of HealthNational guideline committeeSwitzerlandLeague Against CancerCancer societyNorwayCancer Registry of NorwayCancer societyNetherlandsNational Institute for Public Health and the EnvironmentNational guideline committeeGermanyFederal Joint CommitteeNational guideline committeeSwedenNational Board of Health and WelfareNational guideline committeeIrelandNational Screening ServiceNational guideline committeeAustriaAustrian Cancer Aid SocietyCancer societyDenmarkNational Board of HealthNational guideline committeeBelgiumFoundation Against CancerCancer societyCanadaCanadian Task Force for Preventive Health CareNational guideline committeeAustraliaAustralian Government Department of HealthNational guideline committeeFranceNational Cancer InstituteNational guideline committeeJapanNational Cancer CenterNational guideline committeeIcelandIcelandic Cancer SocietyCancer societyUnited KingdomUnited Kingdom National Screening CommitteeNational guideline committeeFinlandCancer Society of FinlandCancer societyNew ZealandMinistry of HealthNational guideline committeeItalyNational Screening ObservatoryNational guideline committeeSpainCancer Strategy of National Health SystemNational guideline committee

Breast cancer screening {#Sec4}
-----------------------

The recommendations for breast cancer screening with mammography are presented in Table [2](#Tab2){ref-type="table"}. Overall, the recommendations for breast cancer are quite similar among the 21 selected countries. The most common screening age ranges are from 50 to 69 years old, and most of those countries are European. Screening for breast cancer every 2 years is recommended in most of the countries. Only Japan does not specify the screening interval. The American College of Radiology has the longest age range for screening and is the only guideline in the world recommending an annual screening interval, while the United Kingdom has the longest screening interval (every 3 years).Table 2Recommendations for breast cancer screening with mammography, in order of overall healthcare spendingType of organization: *A* national guideline committee, *B* cancer society, *C* specialty society, *D* other^1^United States American College of Obstetrics and Gynecology: screening interval of 1 or 2 years^2^Switzerland: screening age of 50--70 years^3^Netherlands: screening age of 50--75 years^4^Sweden: screening interval is 18 months from age 40 to 54 years^5^Canada: screening interval of 2 or 3 years^6^France: screening age of 50--75 years^7^Japan: Do not recommend a screening intervalAbbreviations: *UK* United Kingdom, *USA* United States of America, *NIPHE* National Institute for Public Health and the Environment, *CTFPHC* Canadian Task Force on Preventive Health Care, *NA* not available (cannot find information)\*Consider the person's life expectancy when making a decision

Cervical cancer screening {#Sec5}
-------------------------

Table [3](#Tab3){ref-type="table"} describes cervical cancer screening's recommendations. Luxembourg is the only country with no national recommendation identified for cervical cancer screening. There was some heterogeneity regarding the recommended tests (cytology, HPV, or both), the age to begin screening, and screening intervals. Most countries recommend an age of initiation of screening from 18 to 29 years and a stopping age between 60 and 70 years. Countries most commonly recommend a screening interval of 3 to 5 years. Six out of the 21 countries have adopted HPV testing as a primary test for cervical cancer screening, and cytology is still predominantly recommended with a screening interval of 3 years.Table 3Recommendations for cervical cancer screening, in order of overall healthcare spendingType of organization: *A* national guideline committee, *B* cancer society, *C* specialty society, *D* otherStart and stop age coding: *wavy border*---not specifiedMost guidelines recommend that screening cease between ages 65 and 70 years in women with consistently normal screening in the previous decade. Screening is not recommended for women who have had a hysterectomy for benign disease^1^USA: screening age of 21--65 years for cytology and 30--65 years for cytology and HPV testing^2^Switzerland: start and stop ages are not recommended^3^Norway: screening age of and 25--69 years for cytology and 34--69 years for HPV testing^4^Netherlands: screening age of 30--60 years^5^Germany: stop age is not recommended^6^Sweden: screening age of 23--29 years for cytology and 30--64 years for HPV testing^7^Ireland: screening age of 25--61 years^8^Austria: stop age is not recommended^9^Denmark: screening age of 23--59 years for cytology and 60--64 years for HPV testing^10^Belgium: screening age of 25--65 years for cytology^11^Australia: screening age of 18--69 years for cytology (current recommendation) and 25--75 years for HPV testing (will implement from December 2017)^12^France: screening age of 25--65 years^13^Japan: stop age and screening interval are not recommended^14^Iceland: screening age of 23--65 years^15^UK: screening age of 25--64 years^16^Finland: screening age of 30--60 years^17^New Zealand: screening age of 20--70 years^18^Italy: screening age of 25--64 years (some programs have moved into 25--30/35 years with cytology and 30/35--64 years with HPV testing)^19^Spain: screening age of 25--65 yearsAbbreviations: *USPSTF* United States Preventive Services Task Force, *NIPHE* National Institute for Public Health and the Environment, *CTFPHC* Canadian Task Force on Preventive Health Care, *NA* not applicable (cannot find information), *Cyt.* cytology, *Cyt + HPV* cytology plus HPV co-testing+Date website with recommendation last updated

Colorectal cancer screening {#Sec6}
---------------------------

Table [4](#Tab4){ref-type="table"} demonstrates the variability in screening recommendations across different countries with respect to both the type and schedule of screening. Even within the USA differences in guidelines exist, as the USPSTF and American Cancer Society (ACS) express no preference concerning the type of test, while the recent joint recommendations from several specialty societies recommend a tiered approach with colonoscopy or fecal immunochemical (FIT) testing offered first \[[@CR17]\]. All other countries recommend a test for fecal occult blood, colonoscopy, or either. Regarding fecal occult blood testing, FIT is generally preferred over gFOBT, especially in more recent guidelines. Concerning the use of colonoscopy as a screening method, the only countries outside the USA that recommend it are Switzerland, Germany, and Austria. In some countries, the infrastructure may be lacking in terms of the number of trained gastroenterologists to support this screening method, although cost and acceptability are also important factors. The results summarized in Table [4](#Tab4){ref-type="table"} reflect no clear association between total healthcare expenditure per capita and colorectal cancer screening recommendations, other than that 4 of 5 countries recommending the shortest screening interval are among the lowest spenders per capita. Notably, only Austria and Japan recommend initiation of screening for average risk persons at age 40.Table 4International colorectal cancer screening recommendations for the general population (persons not at "high-risk"), in order of decreasing total healthcare expenditure per capitaType of organization: *A* national guideline committee, *B* cancer society, *C* specialty society or societies^1^USPSTF and ACS: no preference regarding choice of tests; high sensitivity gFOBT preferred, with recommendation against in-office FIT or gFOBT; FIT-DNA is every 1 or 3 years; FS + FIT is FS every 10 years and FIT annually^2^US Multi-Society Guidelines: consider screening between 75 and 85 if no previous screening^3^Switzerland: or colonoscopy every 10 years^4^Norway: currently being compared to flexible sigmoidoscopy (with screening once every 10 years from age 50 to 74) in a pilot study^5^Germany: beginning at age 55, also obtain colonoscopy every 10 years (at a minimum), stopping after 2 colonoscopies^6^Austria: beginning at age 50, also obtain colonoscopy every 7--10 years^7^Canada: or flexible sigmoidoscopy every 10 years; colonoscopy is not recommended^8^Italy: FIT or flexible sigmoidoscopy once at age 58 or 60, and then FIT every 2 years from age 59 to 69*Abbreviations: USA* United States of America, *Colo* colonoscopy, *CT colo* CT colonography, *FIT* fecal immunochemical test, *gFOBT* guaiac fecal occult blood test, *NIPHE* National Institute for Public Health and the Environment, *CTFPHC* Canadian Task Force on Preventive Health Care, *CSNHS* Cancer Strategy of the National Health System, *AGDH* Australian Government Dept of Health

Prostate cancer screening {#Sec7}
-------------------------

Table [5](#Tab5){ref-type="table"} demonstrates the variability between various countries regarding screening for prostate cancer. Unlike that with the other cancers, the chief disagreement concerning prostate cancer is not between the type and frequency of test but rather whether or not to screen at all. In fact, if one includes the current 2012 USPSTF recommendation, eight countries explicitly recommend against prostate cancer screening. Of the remaining countries that did not recommend against screening, the vast majority did not have an organized national screening program in place, recommended that an individual consult with their physician or did not make a recommendation.Table 5International prostate cancer screening recommendations for the general population (persons not at "high-risk"), in order of decreasing total healthcare expenditure per capitaInterval coding: *vertical cross-hatch* every year, *solid* every 2 years, *diagonal line* no interval providedType of organization: *A* national guideline committee, *B* cancer society, *C* specialty society^1^US American Cancer Society: screening should be done every year if PSA levels are greater than 2.5 ng/mL; stop screening in asymptomatic men with less than 10 years life expectancy; men at increased risk should consider beginning screening at 40 or 45 years^2^US American Urological Association: an interval of 2 years or more is preferred. Additionally, baseline PSA levels can be used to individualize rescreening intervals. Screening should be stopped in asymptomatic men whose life expectancy is less than 10 years^3^Luxembourg: age to start screening not provided. No organized national guidelines; screening based on individual discussion between patient and physician^4^Switzerland: age to start screening not provided. No organized national guidelines; screening based on individual discussion between patient and physician^5^Austria: "Screening should be carried out 'regularly' from the 45th birthday"^6^Belgium: no organized national guidelines; screening based on individual discussion between patient and physician^7^Iceland: no organized national guidelines; screening based on individual discussion between patient and physicianAbbreviations: *USPSTF* United States Preventive Services Task Force, *PSA* prostate-specific antigen, *NIPHE* National Institute for Public Health and the Environment, *DRE* digital rectal examination, *NBHW* National Board of Health and Welfare, *CTFPHC* Canadian Task Force on Preventive Health Care, *AGDH* Australian Government Department of Health, *CSNHS* Cancer Strategy of the National Health System

Skin cancer screening {#Sec8}
---------------------

Most countries included did not make a recommendation regarding skin cancer screening. Only the USA, Germany, Austria, and France address skin cancer screening. The latter three recommend screening, while the USPSTF has determined that there is insufficient evidence to recommend visual skin examination by a physician. Germany recommends that such examination take place every 2 years beginning at age 35, and France provides seven questions for general practitioners to ask their patients in order to assess risk. Uniquely, Austria recommends self-examination and recommends doing so twice a year (before and after the summer months). None of the countries recommending screening provide an age to stop screening.

Lung cancer screening {#Sec9}
---------------------

Among 21 selected countries, only 5 countries have recommendations regarding lung cancer screening (USA, Canada, Japan, United Kingdom, and Australia). Australia and the United Kingdom recommend against lung cancer screening. Both the USPSTF and the Canadian Task Force recommend low-dose computed tomography (CT) for smokers with at least 30 pack-year smoking history and who smoke or quit smoking less than 15 years. However, the USPSTF recommends screening for the age range 55 to 80 years, while the Canadian Task Force recommends screening for a narrower age range from 55 to 74 years, with a screening interval of 1 to 3 years. In contrast to the USA and Canada, Japan recommends chest radiography to screen for lung cancer starting at age 40 years, but concludes that there is insufficient evidence for low-dose CT. Japan does not recommend a stopping age or screening interval. Several European countries have screening trials underway, so these recommendations may change when those results are available \[[@CR18], [@CR19]\].

Association between healthcare expenditures and screening intensity {#Sec10}
-------------------------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} summarizes the relationship between healthcare expenditures and the intensity of screening, measured as the total lifetime number of screening tests recommended for an average risk person for breast, cervical, and colorectal cancer (the latter based on recommendations for use of the FIT). It shows that there is no clear association between expenditures and screening intensity for these cancers, disproving our initial hypothesis. Regarding prostate cancer, 5 of the top 10 countries in terms of healthcare expenditure recommend selective or routine screening, compared with only 2 of the bottom 10 countries. Finally, the three countries recommending lung cancer screening are ranked 1st, 12th, and 15th in spending, again creating no pattern of higher spending equating to higher intensity of screening.Fig. 1This figure shows the relationship between per capita spending on healthcare with the number of lifetime screening tests recommended for **a**) breast cancer (mammography), **b**) cervical cancer (cytology or HPV), and **c**) colorectal cancer (FIT)

Discussion {#Sec11}
==========

We have summarized national screening recommendations for the 21 countries with the highest total healthcare expenditure per capita. These countries were selected because they are likely to have adequate resources for a cancer screening program of some kind; comparison with less well-resourced settings would be unfair and would be less likely to reflect the differences in values, priorities, and the assessment of evidence that we are interested in. As physicians and researchers in the USA, we are especially interested in how our recommendations compare with other countries, and what we can learn from them.

In comparing recommendations, we are not making value judgements or endorsing a single "correct" answer regarding age at initiation, screening interval, or age at cessation of screening. These decisions likely reflect differences between countries and organizations regarding how benefits and harms are valued and balanced at a societal level, the type of evidence considered, the availability of resources and infrastructure for screening (for example, adequate trained medical personnel to perform colonoscopy), whether and how cost is considered, and different standards for assembling, evaluating, and interpreting a complex evidence base. For example, does the body making a recommendation consider only randomized controlled trials with cancer-specific mortality as the outcome, or does it also consider observational data and modeling studies? \[[@CR20]\] Does the panel consider outcomes beyond mortality, such as disease progression, cost, stage shifts, or quality of life? Is cost explicitly considered or is the decision made solely on the balance of potential benefits and harms?

Note that in our discussion below, we consider the USPSTF to represent the US national screening recommendation, although recommendations from USA specialty and cancer societies are also presented. Also, when we use the term "more aggressive" or "more conservative" to describe screening recommendations, we refer to recommendations with a broader age range and/or a more frequent interval vs a narrower age range and/or a less frequent interval. Finally, a review of the process used by each country or organization to develop and update guidelines is beyond the scope of this article.

Commonalities {#Sec12}
-------------

There was considerable homogeneity regarding screening recommendations for breast cancer, cervical cancer, and to some extent, colorectal cancer. A starting age for routine mammography of 50 years was recommended by 16 of 21 countries; all countries but one recommended a biennial interval, and 14 recommended a stopping age of 69 or 70 years. Similarly, most countries recommended cervical cancer screening beginning between 21 and 30 years of age (depending on whether or not testing for human papillomavirus was employed), and most recommended a stopping age between 65 and 70 years. Similarly, most countries recommended that colorectal cancer screening begin at age 50 or 55 years and stop by 75 years. Finally, there is a general consensus against screening for lung cancer and melanoma, with only the USA, Japan, and Canada recommending lung cancer screening and only Germany, Austria, and France recommend some approach to screening for skin cancer.

Differences {#Sec13}
-----------

The approach to screening for cervical cancer is evolving, with some countries still recommending cytology only, some recommending HPV testing or co-testing, and some giving clinicians the option of choosing the favored approach. Four countries (Iceland, UK, Sweden, and Finland) do not recommend screening for colorectal cancer until age 60, compared to start ages between 40 and 50 years for most other countries. The recommended test for colorectal cancer screening also varies. FIT was most widely recommended, while the USPSTF offered seven different options, and Germany and Austria recommended FIT for younger patients followed by a series of colonoscopies. There is considerable heterogeneity regarding prostate cancer screening: seven countries recommend screening for prostate cancer in some form, while eight explicitly recommend against it. This is likely due to variation in how guideline panels assess the potential benefits and harms.

Variation by country and type of organization {#Sec14}
---------------------------------------------

For prostate cancer screening, of the seven countries with a recommendation to screen or screen selectively for prostate cancer, five were from the top half of the selected countries based on per capita health expenditures. Four of the five countries with the shortest interval for colorectal cancer screening (Iceland, UK, Finland, and New Zealand) are among the six lowest spending countries. However, there was no apparent association between per capita health expenditures and the intensity of screening for breast and cervical cancer.

Other than within the USA, there was no clear difference in terms of the intensity of screening recommendations coming from national guideline committees, cancer societies or leagues, and specialty societies. In the USA, the recommendations regarding mammography from the American Cancer Society, American College of Obstetrics and Gynecology, and American College of Radiology were the only ones identified that recommended annual screening and also had longer screening intervals for patients at average risk. The American College of Radiology was the only body that recommended annual mammography starting at age 40 years, with no specified stopping age. On the other hand, there is considerable similarity regarding colorectal cancer screening between the USPSTF, ACS, and specialty society guidelines.

Prostate cancer screening recommendations are now similar between the USPSTF draft recommendation of 2017 and the American Urology Association, and recommendations regarding cervical cancer screening between the USPSTF, ACS, and ACOG are nearly identical. Assuming that they are based on the best available evidence, this kind of "harmonization" between guidelines from different groups within a country sends a clear, unified message to patients and physicians. In the absence of such harmonization, confusion may reign and physicians may do what feels right or what is requested by patients rather than what is supported by the best evidence. Due to medicolegal concerns, some physicians may feel compelled to practice based on the most aggressive set of recommendations or based on patient request. This is especially true in the USA context, where "failure to diagnose" is the most common reason for a malpractice lawsuit \[[@CR21]\].

Conclusions {#Sec15}
===========

Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Per capita healthcare spending among wealthy countries appears to have relatively little impact on recommendations; differences are more likely to stem from variation in how benefit and harm are evaluated, and which evidence is considered. Intellectual and financial conflicts of interest inherent to professional societies may contribute to more aggressive recommendations for breast cancer screening from these groups in the USA. A greater intensity of screening may alter the balance of benefits and harms by increasing the likelihood of direct harms of the screening test, as well as the serious harms associated with overdiagnosis \[[@CR22]\]. In some cases, where specialty societies have adopted more rigorous methods, their recommendations have become more conservative, as when the American Urologic Association moved from a consensus to an evidence-based process \[[@CR23]\]. Of course, one could also argue that national bodies like the USPSTF or Canadian Task Force are overly conservative since they rely largely on randomized trials and modeling for their recommendations. And, even groups using similarly rigorous methods may reach different conclusions, with USA and Canadian recommendations for colorectal cancer screening a good example.

In conclusion, we encourage the formation of independent panels of experts in each country, modeled after the USPSTF, Canadian Task Force, and the UK National Screening Committee. These panels should make independent, evidence-based recommendations regarding screening that assess the benefits, harms, and available resources in that country's context. Consistent with IOM recommendations, the panels should include primary care physicians, patients, methodologic experts and relevant subspecialists, recommendations should be regularly updated, and panel members should be free of financial and intellectual conflict of interest to the greatest extent possible \[[@CR24]\].

Appendix {#Sec16}
========

Table 6The references of the national recommendations for breast, cervical, colorectal, prostate, skin, and lung cancer screening by countryCountryReferenceYear of recommendation or most recent updateBreast cancer United States (USPSTF)<https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening1>2016 United States (ACS)<https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html>2015 United States (ACOG)<http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Breast-Cancer-Screening>2017 United States (ACR)<https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Breast-Cancer-Screening-for-Average-Risk-Women>2017 Luxembourg (Ministry of Health)<https://plancancer.lu/about/depistage/cancer-du-sein/depistage-actuel-cancer-du-sein/>NA Switzerland (League Against Cancer)[https://www.liguecancer.ch/prevenir-le-cancer/depistage-et-prevention-du-cancer/cancer-du-sein/depistage-par-mammographie/](https://www.liguecancer.ch/prevenir-le-cancer/depistage-et-prevention-du-cancer/cancer-du-sein/depistage-par-mammographie)\
<https://www.swisscancerscreening.ch/fr/cancer-du-sein/informations-generales/mammographie>2016 Norway (Cancer Registry of Norway)<https://www.kreftregisteret.no/en/screening/Breast-Cancer-Screening-Programme>2010 Netherlands (NIPHE)<http://www.rivm.nl/en/Topics/B/Breast_cancer_screening_programme>2017 Germany (Federal Joint Committee)[https://www.g-ba.de/institution/themenschwerpunkte/frueherkennung/krebsfrueherkennung/](https://www.g-ba.de/institution/themenschwerpunkte/frueherkennung/krebsfrueherkennung)2015 Sweden (National Board of Health and Welfare)<http://www.socialstyrelsen.se/riktlinjer/nationellascreeningprogram/brostcancer-screeningmedmammog>2013 Ireland (National Screening Service)<http://www.screeningservice.ie/screening.html>NA Austria (Austrian Cancer Aid Society)[https://www.krebshilfe.net/information/krebs-vorsorge/mammografie-screening/](https://www.krebshilfe.net/information/krebs-vorsorge/mammografie-screening)\
<https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_cancerscreening_2ndreportimplementation_en.pdf>2014 Denmark (National Board of Health)<https://www.sst.dk/da/udgivelser/2014/~/media/31CB15B2A39E4A3EB198B9486F66B4A2.ashx>2014 Belgium (Foundation Against Cancer)<http://www.cancer.be/les-cancers/types-de-cancers/cancer-du-sein/examens>2017 Canada (CTFPHC)[http://canadiantaskforce.ca/guidelines/published-guidelines/breast-cancer/](http://canadiantaskforce.ca/guidelines/published-guidelines/breast-cancer)2011 Australia (Australian Government Department of Health)<http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/breast-screening-1>2015 France (National Cancer Institute)<http://www.e-cancer.fr/Professionnels-de-sante/Depistage-et-detection-precoce/Depistage-du-cancer-du-sein/Orienter-vos-patientes>2015 Japan (National Cancer Center)<http://canscreen.ncc.go.jp/guideline/nyugan.html>2016 Iceland (Icelandic Cancer Society)<https://www.krabb.is/leitarstod/um-leitarstodina/af-hverju-brjostakrabbameinsleit/leit-ad-krabbameini-i-brjostum-1>NA UK (UK National Screening Committee)<https://legacyscreening.phe.org.uk/breastcancer>\
<http://www.nhs.uk/Conditions/breast-cancer-screening/Pages/When-its-offered.aspx>2012 Finland (Cancer Society of Finland)[https://www.cancer.fi/syoparekisteri/en/mass-screening-registry/breast_cancer_screening/screening_programme/](https://www.cancer.fi/syoparekisteri/en/mass-screening-registry/breast_cancer_screening/screening_programme)\
<https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_cancerscreening_2ndreportimplementation_en.pdf>2010 New Zealand (Ministry of Health)<https://www.nsu.govt.nz/breastscreen-aotearoa/what-breast-cancer>2014 Italy (National Screening Observatory)<http://www.osservatorionazionalescreening.it/sites/default/files/allegati/ONS_2015_full.pdf>2015 Spain (Cancer Strategy of National Health System)<http://www.msps.es/organizacion/sns/planCalidadSNS/pdf/ActualizacionEstrategiaCancer.pdf>2009Cervical cancer United States (USPSTF)<https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervical-cancer-screening>2012 United States (ACS)<https://www.cancer.org/cancer/cervical-cancer/prevention-and-early-detection/cervical-cancer-screening-guidelines.html>2016 United States (ACOG)<http://www.acog.org/Patients/FAQs/Cervical-Cancer-Screening>2016 Luxembourg (Ministry of Health)[https://plancancer.lu/about/depistage/cancer-du-col-de-luterus/depistage-actuel-cancer-du-col-de-luterus/](https://plancancer.lu/about/depistage/cancer-du-col-de-luterus/depistage-actuel-cancer-du-col-de-luterus) Switzerland (League Against Cancer)[https://www.liguecancer.ch/prevenir-le-cancer/depistage-et-prevention-du-cancer/cancer-du-col-de-luterus/prevention-et-depistage-du-cancer-du-col-de-luterus/](https://www.liguecancer.ch/prevenir-le-cancer/depistage-et-prevention-du-cancer/cancer-du-col-de-luterus/prevention-et-depistage-du-cancer-du-col-de-luterus)2010 Norway (Cancer Registry of Norway)[https://www.kreftregisteret.no/en/screening/Cervical-Cancer-Screening-Programme/](https://www.kreftregisteret.no/en/screening/Cervical-Cancer-Screening-Programme)\
<https://www.kreftregisteret.no/globalassets/masseundersokelsen-mot-livmorhalskreft/algoritme-hpv-test-i-primarscreening-ny-april-2015.jpg>2010 Netherlands (NIPHE)<http://www.rivm.nl/en/Topics/C/Cervical_cancer_screening_programme>2015 Germany (Federal Joint Committee)[https://www.g-ba.de/institution/themenschwerpunkte/frueherkennung/krebsfrueherkennung/](https://www.g-ba.de/institution/themenschwerpunkte/frueherkennung/krebsfrueherkennung)2015 Sweden (National Board of Health and Welfare)<http://www.socialstyrelsen.se/riktlinjer/nationellascreeningprogram/livmoderhalscancer-screeningme>2014 Ireland (National Screening Service)<http://www.screeningservice.ie/cervical.html>2009 Austria (Austrian Cancer Aid Society)[https://www.krebshilfe.net/information/krebs-vorsorge/frauen/](https://www.krebshilfe.net/information/krebs-vorsorge/frauen)NR Denmark (National Board of Health)<https://www.sst.dk/da/udgivelser/2014/~/media/31CB15B2A39E4A3EB198B9486F66B4A2.ashx>2014 Belgium (Foundation Against Cancer)<http://www.cancer.be/les-cancers-types-de-cancers-liste-z-cancer-du-col-de-lut-rus/examens>2017 Canada (CTFPHC)[http://canadiantaskforce.ca/guidelines/published-guidelines/cervical-cancer/](http://canadiantaskforce.ca/guidelines/published-guidelines/cervical-cancer)2013 Australia (Australian Government Department of Health)<http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-screening-1>2017 France (National Cancer Institute)<http://www.e-cancer.fr/Professionnels-de-sante/Depistage-et-detection-precoce/Depistage-du-cancer-du-col-de-l-uterus/Le-depistage-par-frottis-cervico-uterin>2017 Japan (National Cancer Center)<http://canscreen.ncc.go.jp/guideline/shikyukeigan.html>\
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